No connection

Search Results

RMTI

BEARISH
$0.91 Live
Rockwell Medical, Inc. · NASDAQ
Target $3.0 (+228.3%)
$0.78 52W Range $2.1

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 19, 2026
Market cap
$36.0M
P/E
N/A
ROE
-15.3%
Profit margin
-7.7%
Debt/Equity
0.34
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
RMTI exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across profitability and operational efficiency. Despite a strong current ratio of 3.98 and low debt-to-equity, the company is suffering from a significant revenue contraction of -25.60% YoY and consistent earnings misses (0/4 beats in the last year). The disconnect between the analyst target price of $3.00 and the actual fundamental decay, coupled with bearish insider selling, suggests a high-risk speculative profile.

Key Strengths

Strong short-term liquidity with a current ratio of 3.98
Low leverage with a Debt/Equity ratio of 0.34
Trading slightly below book value (P/B 0.97)
Low Price-to-Sales ratio (0.52) suggesting low valuation relative to revenue
Positive gross margin (16.89%) indicating core product viability

Key Risks

Severe revenue decline (-25.60% YoY and Q/Q)
Consistent failure to meet earnings estimates (Average surprise -80.56%)
Negative ROE (-15.28%) and negative profit margins
Bearish insider sentiment with sales from CFO, COO, and Director
Extreme long-term price erosion (-90.9% over 5 years)
AI Fair Value Estimate
Based on comprehensive analysis
$0.85
-7.0% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
18
Weak
Value
45
Future
15
Past
10
Health
20
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Negative Revenue Growth, Bearish Insider Activity, Consistent Earnings Misses
Confidence
85%
Value
45/100

Ref P/E N/A, PEG 4.43, P/B 0.97

Positives
  • P/B under 1.0
  • Low P/S ratio
Watchpoints
  • Negative earnings make P/E irrelevant
  • High PEG ratio (4.43)
Future
15/100

Ref Growth rates and Earnings track record

Positives
  • Analyst target price suggests potential upside
Watchpoints
  • Revenue growth is sharply negative (-25.6%)
  • Earnings surprises are deeply negative
Past
10/100

Ref Historical price trends

Positives
No standout positives identified.
Watchpoints
  • 5-year price change of -90.9%
  • Consistent trend of negative earnings
Health
20/100

Ref Piotroski F-Score 1/9

Positives
  • High current ratio
  • Low debt/equity
Watchpoints
  • Piotroski F-Score of 1/9 indicates fundamental failure
Dividend
0/100

Ref Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend payments

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.91
Analyst Target
$3.0
Upside/Downside
+228.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for RMTI and closest competitors.

Updated 2026-04-17
RMT
Rockwell Medical, Inc.
Primary
5Y
-90.9%
3Y
-57.7%
1Y
-11.7%
6M
-22.2%
1M
-11.7%
1W
0.0%
RAD
Radiopharm Theranostics Limited
Peer
5Y
-74.1%
3Y
-74.1%
1Y
+6.5%
6M
-35.6%
1M
-2.5%
1W
-1.7%
PLU
Pluri Inc.
Peer
5Y
-89.3%
3Y
-51.8%
1Y
-3.0%
6M
-19.3%
1M
+8.7%
1W
+3.5%
NMT
NeuroOne Medical Technologies Corporation
Peer
5Y
-88.5%
3Y
-57.8%
1Y
+32.2%
6M
-19.5%
1M
+1.4%
1W
-12.1%
ATR
Atara Biotherapeutics, Inc.
Peer
5Y
-98.9%
3Y
-95.6%
1Y
-24.7%
6M
-54.9%
1M
-70.3%
1W
+15.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
13.05
PEG Ratio
4.43
P/B Ratio
0.97
P/S Ratio
0.52
EV/Revenue
0.34
EV/EBITDA
-9.4
Market Cap
$36.0M

Profitability

Profit margins and return metrics

Profit Margin -7.67%
Operating Margin -2.17%
Gross Margin 16.89%
ROE -15.28%
ROA -5.04%

Growth

Revenue and earnings growth rates

Revenue Growth -25.6%
Earnings Growth N/A
Q/Q Revenue Growth -25.62%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.34
Low debt
Current Ratio
3.98
Strong
Quick Ratio
3.46
Excellent
Cash/Share
$0.63

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
21.1%
Op. Margin
-2.2%
Net Margin
-3.0%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.55x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
96%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-03-26
$-0.01
-150.0% surprise
2025-11-12
$-0.05
-11.1% surprise
2025-08-14
$-0.05

Healthcare Sector Comparison

Comparing RMTI against 447 companies in the Healthcare sector (26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
-15.28%
This Stock
vs
-97.42%
Sector Avg
-84.3% (Below Avg)
Profit Margin
-7.67%
This Stock
vs
-14.95%
Sector Avg
-48.7% (Weaker)
Debt to Equity
0.34
This Stock
vs
3.06
Sector Avg
-89.0% (Less Debt)
Revenue Growth
-25.6%
This Stock
vs
147.85%
Sector Avg
-117.3% (Slower)
Current Ratio
3.98
This Stock
vs
4.68
Sector Avg
-14.8% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

NERI JESSE
Chief Financial Officer
Sell
2026-01-02
886 shares · $740
HUNTER HEATHER R.
Chief Operating Officer
Sell
2026-01-02
2,868 shares · $2,396
COOPER JOHN G
Director
Sell
2025-11-18
5,079 shares · $4,419
DAWSON JOSEPH H.
Director
Stock Award
2025-11-17
25,000 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

10-K
10-K
2026-03-26

RMTI filed its annual 10-K report on March 26, 2026. The provided excerpts do not contain specific financial metrics or detailed risk disclosures, limiting the available analysis of the company's financial performance and risk profile.

8-K
8-K
2026-03-26
8-K
8-K
2026-03-26
8-K
8-K
2026-01-20
8-K
8-K
2026-01-05
8-K
FORM 8-K
2025-11-18
8-K
8-K
2025-11-12
10-Q
10-Q
2025-11-12

RMTI's 10-Q filing dated November 12, 2025, highlights significant financial risks, specifically noting defaults upon senior securities. The company also reports unregistered sales of equity securities, indicating active capital raising efforts to address its financial position.

8-K
8-K
2025-11-12

RMTI filed an 8-K on November 12, 2025, likely to announce its third-quarter financial results.

8-K
FORM 8-K
2025-09-29
8-K
8-K
2025-08-14
10-Q
10-Q
2025-08-14
8-K
FORM 8-K
2025-05-20
8-K
8-K
2025-05-12
8-K
FORM 8-K
2025-05-12
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
2 analysts
HC Wainwright & Co.
2026-03-30
Maintains
Buy Buy
HC Wainwright & Co.
2026-01-26
reit
Buy Buy
HC Wainwright & Co.
2025-11-13
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning RMTI from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile